Abasaglar ® (insulin glargin)

För fullständig produktresumé för Abasaglar® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Abasaglar® (insulin glargin): Byte från insulin detemir

Baserat på studieanalyser kan en dosreduktion vara nödvändig vid övergång från insulin detemir till Abasaglar.

Detailed Information

No dedicated trial has been conducted to investigate patients transitioning from IDet to Abasaglar.

To compare insulin doses in patients treated with IGlar or IDet, Wallace et al conducted an analysis that included

  • 5 large RCTs in patients with T2DM, and

  • 2 large RCTs in patients with T1DM.1

To achieve the same glycemic control, patients treated with IDet required an average 38% higher dose of insulin compared with patients treated with IGlar (Table 1 ).1

Dailey et al conducted a pooled analysis of 22 RCTs in patients with T2DM to compare insulin doses in patients treated with IGlar or IDet. To achieve a similar reduction in HbA1c levels, patients treated with IDet required a 31% higher mean insulin dose compared with patients treated with IGlar ( Table 1).2

Table 1. Analysis of Doses in Patients Treated With Insulin Glargine or Insulin Detemir in Randomized Controlled Trials1,2

Trial

Analysis

Patient Population

Doses of Insulin Glargine Compared With Insulin Detemir for Similar HbA1c Reduction

Wallace et al

7 RCTsa

T1DM and T2DM

8.0%-77.2% (average 38%) higher detemir dose

Dailey et al

22 RCTs

T2DM

0.59 (0.07)b units/kg for insulin detemirc

0.45 (0.02)b units/kg for insulin glargine

Abbreviations: HbA1c = glycated hemoglobin; RCT = randomized controlled trial; T1DM = patients with type 1 diabetes mellitus; T2DM = patients with type 2 diabetes mellitus.

a Five RCTs in patients with T2DM and 2 RCTs in patients with T1DM.

b Mean (SE).

c Represents a 31% higher insulin dose compared to insulin glargine.

Wallace et al concluded that since higher doses of IDet may be needed to obtain similar glycemic control, prescribers may want to consider a dosage reduction when transitioning from IDet to IGlar in order to reduce the risk of hypoglycemia that may result when using a unit-to-unit conversion.1

General Dosing Guidelines When Transitioning to Abasaglar

If transitioning from a treatment regimen with an intermediate- or long-acting insulin, other than an IG-100 product, to a regimen with [Preferred Product Name],

  • a change in the dose of the basal insulin may be required, and

  • the doses and timing of concurrent rapid- or short-acting insulins or other concomitant antihyperglycemic medications may need to be adjusted.3

References

1. Wallace JP, Wallace JL, McFarland MS. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother. 2014;48(3):361‑368. http://dx.doi.org/10.1177/1060028013518420

2. Dailey G, Admane K, Mercier F, Owens D. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther. 2010;12(12):1019-1027. http://dx.doi.org/10.1089/dia.2010.0063

3. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

HbA1c = glycated hemoglobin

IDet = insulin detemir

IG-100 = insulin glargine 100 units/mL

RCT = randomized controlled trial

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Datum fӧr senaste ӧversyn 2020 M01 07


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss